TY - JOUR
T1 - The tale of TILs in breast cancer
T2 - a report from the International Immuno-Oncology Biomarker Working Group
AU - El Bairi, Khalid
AU - Haynes, Harry R.
AU - Blackley, Elizabeth
AU - Fineberg, Susan
AU - Shear, Jeffrey
AU - Turner, Sophia
AU - de Freitas, Juliana Ribeiro
AU - Sur, Daniel
AU - Amendola, Luis Claudio
AU - Gharib, Masoumeh
AU - Kallala, Amine
AU - Arun, Indu
AU - Azmoudeh-Ardalan, Farid
AU - Fujimoto, Luciana
AU - Sua, Luz F.
AU - Liu, Shi-Wei
AU - Lien, Huang-Chun
AU - Kirtani, Pawan
AU - Balancin, Marcelo
AU - El Attar, Hicham
AU - Guleria, Prerna
AU - Yang, Wenxian
AU - Shash, Emad
AU - Chen, I-Chun
AU - Bautista, Veronica
AU - Do Prado Moura, Jose Fernando
AU - Rapoport, Bernardo L.
AU - Castaneda, Carlos
AU - Spengler, Eunice
AU - Acosta-Haab, Gabriela
AU - Frahm, Isabel
AU - Sanchez, Joselyn
AU - Castillo, Miluska
AU - Bouchmaa, Najat
AU - Md Zin, Reena R.
AU - Shui, Ruohong
AU - Onyuma, Timothy
AU - Yang, Wentao
AU - Husain, Zaheed
AU - Willard-Gallo, Karen
AU - Coosemans, An
AU - Perez, Edith A.
AU - Provenzano, Elena
AU - Ericsson, Paula Gonzalez
AU - Richardet, Eduardo
AU - Mehrotra, Ravi
AU - Sarancone, Sandra
AU - Ehinger, Anna
AU - Rimm, David L.
AU - Bartlett, John M. S.
AU - Viale, Giuseppe
AU - Denkert, Carsten
AU - Hida, Akira I.
AU - Sotiriou, Christos
AU - Loibl, Sibylle
AU - Hewitt, Stephen M.
AU - Badve, Sunil
AU - Symmans, William Fraser
AU - Kim, Rim S.
AU - Pruneri, Giancarlo
AU - Goel, Shom
AU - Francis, Prudence A.
AU - Inurrigarro, Gloria
AU - Yamaguchi, Rin
AU - Garcia-Rivello, Hernan
AU - Horlings, Hugo
AU - Afqir, Said
AU - Salgado, Roberto
AU - Adams, Sylvia
AU - Kok, Marleen
AU - Dieci, Maria Vittoria
AU - Michiels, Stefan
AU - Demaria, Sandra
AU - Loi, Sherene
AU - the International Immuno-Oncology Biomarker Working Group
AU - Schelfhout, Vera
AU - Arbzadeh, Elham
AU - Bondanar, Anastasiya
AU - Reyes, Silvio Antonio Galeano
AU - Ruz, Jose Ramirez
AU - Kang, Jun
AU - Xiang, Lu
AU - Zimovjanova, Martina
AU - Togores, Pilar
AU - Ozturk, Tulin
AU - Patil, Asawari
AU - Corpa, Marcus
AU - Whitehouse, Ann
AU - Tan, Benjamin
AU - de Paula, Alfredo
AU - Rossetti, Claudia
AU - Lang-Schwarz, Corinna
AU - Mahon, Sarah
AU - Giacometti, Cinzia
AU - Linderholm, Barbro
AU - Deman, Frederik
AU - Montagna, Giacomo
AU - Gong, Gyungyub
AU - Pavcovich, Marta
AU - Chaer, Yeesoo
AU - Cabrero, Isabel Alvarado
AU - de Brito, Mayana Lopes
AU - Ilieva, Nevena
AU - Fulop, Annamaria
AU - Souza, Maiara
AU - Bilancia, Domenico
AU - Idowu, Michael
AU - Johri, Ritika
AU - Szpor, Joanna
AU - Bachani, Lira
AU - Schmitt, Fernando
AU - Giannotti, Mag
AU - Kurebayashi, Yutaka
AU - Ramirez, Bruno Elias Anota
AU - Salido, Eduardo
AU - Bortesi, Laura
AU - Bonetto, Sara
AU - Elomina, Kevin
AU - Lopez, Patricia
AU - Sharma, Vijay
AU - Edirisinghe, Amalika
AU - Mathur, Dhanvi
AU - Sahay, Ayushi
AU - Mouloud, Makhlouf Ait
AU - Giang, Chau Huynh
AU - Mukolwe, Edwin
AU - Kiruka, Edgar
AU - Samberg, Nancy
AU - Abe, Norie
AU - Brown, Mark
AU - Millar, Ewan
AU - Li, Xiaoxian (Bill)
AU - Yuan, Zheng
AU - Pasupathy, Asokan
AU - Miele, Raffaele
AU - Luff, Ronald
AU - e Porfirio, Monica Modesto Araujo
AU - Ajemba, Ogugua
AU - Soni, Rashida
AU - Orvieto, Enrico
AU - DiMaio, Michael
AU - Thomas, Jeremy
AU - Merard, Reena
AU - Subramaniam, Manish Mani
AU - Apolinario, Thiago
AU - Preda, Ovidiu
AU - Preda, Ricardo
AU - Makanga, Alexander
AU - Maior, Marcelo Souto
AU - Li, Lingyu
AU - Saghatchian, Mahasti
AU - Saurine, Tricia
AU - Janssen, Emiel
AU - Cochran, John
AU - Vlada, Nikitina
AU - Cappellesso, Rocco
AU - Elfer, Katherine
AU - Hollick, Morven
AU - Desai, Sangeeta
AU - Oner, Gizem
AU - Schreurs, Arthur
AU - Liu, Steve
AU - Perera, Rashindrie
AU - Mercurio, Paola
AU - Garcia, Felip
AU - Hosny, Kareem
AU - Matsumoto, Hirofumi
AU - van Deurzen, Carolien
AU - Bianchini, Giampaolo
AU - Coban, Ipek
AU - Jahangir, Arif
AU - Rahman, Arman
AU - Stover, Daniel
AU - Luz, Paulo
AU - Martel, Anne
AU - Waumans, Yannick
AU - Stenzinger, Albrecht
AU - Cortes, Javier
AU - Dimitrova, Polina
AU - Nauwelaers, Inne
AU - Velasco, Montse
AU - Fan, Fang
AU - Akturk, Guray
AU - Firer, Michael
AU - Roxanis, Ioannis
AU - Schneck, Mary
AU - Wen, Hannah
AU - Cockenpot, Vincent
AU - Konstantinov, Aleksei
AU - Calatrava, Ana
AU - Vidya, M. N.
AU - Choi, Hyun Joo
AU - Jank, Paul
AU - Hyyti ÇÏinen, Aini
AU - Sabanathan, Dhanusha
N1 - Copyright the Author(s) 2021. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.
AB - The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.
UR - http://www.scopus.com/inward/record.url?scp=85120908291&partnerID=8YFLogxK
U2 - 10.1038/s41523-021-00346-1
DO - 10.1038/s41523-021-00346-1
M3 - Review article
C2 - 34853355
AN - SCOPUS:85120908291
SN - 2374-4677
VL - 7
SP - 1
EP - 17
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 150
ER -